Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Apr 01 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced today that its partner, Centessa Pharmaceuticals Limited, was acquired by Eli Lilly and Company.
According to the acquisition agreement signed on March 31, 2026, Lilly will obtain Centessa’s OX2 receptor agonist series, which includes cleminorexton/ORX750, ORX142, and ORX489. Developed jointly with Nxera Pharma through Centessa’s access to Nxera’s proprietary NxStaR™ technology, these compounds continue to retain milestone payments and royalties for Nxera Pharma. Christopher Kargil, CEO of Nxera Pharma, commented, “We highly value Centessa’s progress in advancing their OX2 receptor agonists towards clinical development stages and believe these candidates hold best-in-class potential for patients suffering from sleep-wake disorders. We look forward to seeing further advancements under Lilly’s leadership.” This transaction underscores Nxera Pharma’s strength and track record in central nervous system drug discovery.
Currently, several drug candidates derived from the company’s NxStaR™ and NxWave™ GPCR structure-based drug discovery platforms are progressing towards late-stage clinical development through partnerships with leading pharmaceutical companies worldwide. In addition, Nxera Pharma maintains a partnership with Lilly since 2022 aimed at developing multiple targets related to metabolic diseases and rare endocrine disorders. Under this collaboration, Nxera Pharma retains rights to receive up to $694 million milestone payments and tiered royalties based on global sales. The impact on Nxera Pharma’s fiscal year ending December 2026 is expected to be neutral; however, the deal is anticipated to contribute positively to the company’s long-term revenue growth and enterprise value.
🟢 Confidence: High AI-translated content.